Free tool
FAERS Monitor: Tevimbra
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761380 or its brand name (Tevimbra, Islelizumab-Jsgr). Reports on generic versions are filed under their own applications.
Reports
224
Serious
220
98% of reports
Hospitalization
64
Death reported
38
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- disease progression80
- off label use26
- malignant neoplasm progression25
- anaemia21
- thrombocytopenia21
- lymphadenopathy19
- pneumonia12
- decreased appetite10
- richter^s syndrome10
- death9
- pyrexia9
- hyponatraemia8
- neutrophil count decreased7
- c-reactive protein increased6
- infusion related reaction6
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2023 | 6 |
| 2024 | 19 |
| 2025 | 72 |
| 2026 | 127 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,935 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| disease progressionSignal | 80 | 63.5 | 53.3 | 4,885 |
| lymphadenopathySignal | 19 | 50.4 | 32.8 | 873 |
| malignant neoplasm progressionSignal | 25 | 22.9 | 15.8 | 505 |
| thrombocytopeniaSignal | 21 | 17.6 | 11.7 | 315 |
| neutrophil count decreasedSignal | 7 | 16.1 | 7.8 | 85 |
| c-reactive protein increasedSignal | 6 | 15.5 | 7.0 | 68 |
| hyponatraemiaSignal | 8 | 13.3 | 6.8 | 80 |
| anaemiaSignal | 21 | 10.3 | 6.9 | 169 |
| infusion related reactionSignal | 6 | 8.5 | 3.9 | 33 |
| decreased appetiteSignal | 10 | 4.0 | 2.2 | 20 |
| pneumoniaSignal | 12 | 3.5 | 2.0 | 19 |
| off label useSignal | 26 | 2.8 | 1.9 | 29 |
| pyrexiaSignal | 9 | 2.4 | 1.3 | 6 |
| death | 9 | 1.0 | 0.5 | 0 |
| richter^s syndrome | 10 | 0.0 | 0.0 | 848,266 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.